Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.


Manufacture Small Molecules

Codes, Drugs, and Rock ‘n’ Roll

| Mark Davison

Europe has set the stage for safer supply chains with its Falsified Medicines Directive. Next, the spotlight could fall on using serialization to boost patient centricity.

Manufacture Packaging

Packaging the Future

| Mike Schäfers

The term ‘packaging’ may not immediately evoke excitement – but without innovation in the field, some therapies wouldn’t even reach market. In other words, don’t judge a box by its cover because there’s more to packaging than meets the eye… and even more lies on the horizon.

Manufacture Packaging

Glass delamination brought under control

Dr. Bernhard Hladik from SCHOTT breaks down the delamination phenomenon and describes how pharma manufacturers can effectively fight back.

Discovery & Development Packaging

Beyond Keeping Up Appearances

| Charlotte Miller

You have the perfect drug and the right packaging to protect it. All is well until the medication reaches the patient, who habitually pops the tablets into another container for easy storage or leaves them exposed to the atmosphere. Film coatings are more than just a pretty face.

Discovery & Development Packaging

Breaking Glass

| Holger Krenz

Glass is the most important primary packaging material for injectable drugs, but the demanding requirements of today’s sensitive biologicals mean that we must consider newer, safer alternatives.

Manufacture Quality & Compliance

Vendors Reloaded

Medicine packaging leaders forming the “Matrix Alliance” will bring improved container and closure systems to market.

Manufacture Packaging

Lost in Translation

Translating medicine packaging information for international markets is a major challenge.

Manufacture Standards & Regulation

Competition Crackdown

The UK Competition and Markets Authority (CMA) has handed out a £37.6 million fine to GSK for paying out “value transfers totaling over 50 million pounds” to competitors between 2001 and 2004 to delay the introduction of generic versions of its branded anti-depressant drug, Seroxat (paroxetine).

Discovery & Development Business Practice

Thinking Inside – and Outside – the Box

Sitting Down With... Diane Paskiet, Director of Scientific Affairs at West Pharmaceutical Services, USA.

Manufacture Drug Delivery

Aptar Pharma’s Ophthalmic Squeeze Dispenser – Innovation based on experience

| Sponsored by Aptar

Although the discussion about the use of preservatives is still somewhat controversial, clinical evidence suggests that patients benefit from unpreserved eye drops especially in chronic conditions.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine